Last week, Cold Spring Harbor Laboratory welcomed 26 trainees, 31 lecturers, and 2 new additional instructors to the biennial Workshop on Pancreatic Cancer. The course, just four iterations young, has substantially grown over the last six years, reflecting the growth in the field. Our conversation with the four instructors Dafna Bar-Sagi, Howard Crawford, Tony Hollingsworth, and David Tuveson illustrates how pancreas cancer research continues to evolve and progress. We also discuss developments that may be game changers, as well as advice for those interested in the field or who wish to attend a future iteration of the course.
To start, here is a brief history of the course as told by Dafna and David – the two instructors who have been with the course since its premiere.
David: The pancreas cancer course started in 2011. There hadn’t been an instructional course in pancreatic cancer before that time and Jim Watson felt strongly that that was one of the reasons why the field was going so slowly. He convinced Dafna Bar-Sagi to organize such a course and, around this time, I was engaged with Jim Watson and Bruce Stillman on a number of issues involving pancreatic cancer so they asked me to help Dafna.
The first course was held that summer with 19 selected trainees who were students, postdocs, junior faculty, as well as some senior faculty. We assembled 19 lecturers to have an intensive workshop at the Banbury Center to go over aspects of pancreatic cancer medicine and science.
Dafna: We almost ran through the entire research community when we first organized the course. Fortunately, for a lot of reasons – funding, publicity for the disease – there are more investigators studying it so we now have a fantastic resource of people looking at the disease from many different perspectives. Now we have to actually leave out great people because there are so many to choose from.
We opened the discussion with how both the course and the field have changed since 2011:
Dafna: The thinking now is less about the tumor cell itself and more about the environment, and putting more weight towards what we call the tumor microenvironment. There is a recognition that it’s not just the genetics of the tumor but how the tumor cells themselves talk to cells in the organ that are doing a lot of important things. Talks that address either partly or completely the role of the tumor microenvironment made up a lot of the talks we heard and what I sense to be exciting to our participants.
David: This year’s course, compared to just six years ago, has more to tell people because in the last six years we’ve learned a lot about pancreatic cancer - not about the medicine but about the science underneath it. We now know genetic events in pancreatic cancer, and we’ve developed methods to study the disease that are much deeper and much more facile than they were even six years ago.
Howard: Scientifically, we’re definitely up-to-date. That’s the nice thing about having four organizers and making these decisions together. It’s not very difficult to incorporate new science.
Tony: In general, there is more discussion now of opportunities compared to the large number of talks about infrastructure before. In the early days, people were still trying to build programs of research – it was an emerging field – which have come together now. As a result, there’s a lot more collaboration going on and more institutionalized programs are making progress.
Something else that’s different in the course are the student presentations that have been incorporated into the curriculum. They’re very effective and very good for engaging the young people with the faculty to discuss a lot of ideas that are going on in their labs right now.
David: The students today are much more informed because they come to the course knowing a lot about pancreatic cancer whereas, in the past, they came to the course to learn what was pancreatic cancer. And so the quality of the students as well as the knowledge of the disease has made it so now we get twice as many applicants as we have spots.
Our conversation then transitioned to the lecturers, topics presented, and exciting new developments:
Howard: Having our lecturers as part of the audience gives the impression of "no holds barred." As a result, the trainees understand early on that there will be questions and challenges, and that it's alright. They also get more comfortable inside the room to be able to bring up any topic that's in their mind.
David: There were a number of lectures this week that were extremely exciting. One was by Dieter Saur who is a professor in Munich, Germany. He’s developed the next version of a mouse model of pancreatic cancer where you can turn genes on and off at different times. In fact, he has gone to the level of making the first known pig model of pancreatic cancer, which looks intriguing and promising and a bit scary.
There was also a lecture by Matthew Vander Heiden who is a well-known biochemist and metabolism researcher. Matthew has identified new pathways that are required by pancreatic cancer to survive. I think his work is groundbreaking and will pave the way for many additional investigators.
And finally, one of our course instructors, Dafna Bar-Sagi has identified two methods by which pancreatic cancer cells evade therapy and survive in a hostile environment. One is they eat their surroundings to live – that’s where they get their food, by eating what’s around them. And the second is they have a stress pathway they activate to prevent responding to therapies. Both of her observations can lead to brand new therapeutic approaches.
Tony: There is a coalescence of ideas of early detection that are coming together. I think the basic studies in the field are really making progress. There’s been development of new complementary model systems – organoids and different animal models – to go along with the existing studies. Also, there is more focus on human studies now than there was for a long time.
Howard: I’d like to re-emphasize that. The idea that there are these new models – organoids and new mouse models and such – and essentially everyone knows they’re available. The students don’t just hear about them but get help developing them in their own laboratory. I think that’s huge. The camaraderie of these workshops is one of the biggest selling points. It gives the students things they can take back to the lab, and the connections to help implement them.
Tony: I think it’s notable that a lot of students from previous workshops are now in faculty positions and are participating in this workshop as lecturers.
Howard: At least two alumni are presenting this year – Mara Sherman and Jenn Bailey.
Dafna: It’s extremely rewarding. Mara Sherman attended as a trainee in 2013 while she was a postdoc in a lab that didn’t work on pancreatic cancer, and she is now an independent investigator in Oregon. We invited her to be a lecturer this year because obviously she’s very driven to do pancreatic cancer research. But Mara will also say herself that attending this workshop was a very reinforcing experience.
For those interested in applying for the Workshop on Pancreatic Cancer, here is additional insight from two of the instructors:
Dafna: This is the only existing opportunity in the field of its kind. It is an immersion course in everything that has to do with the disease. The beauty of this course is that in 5-6 days you are exposed to everything you need to know if you are either going into the field or want to understand the evolving trends. A lot of our lecturers talk about unpublished data. The course is a combination of didactic components so people can actually understand the field, but then it gets into things that are new and exciting that very few actually know about. These are things that aren’t talked about at meetings. It’s a comprehensive way of getting to know everything you need to know about pancreas cancer.
David: For people interested in the course, I would recommend they get in line now. The Workshop on Pancreatic Cancer is the rock concert you don’t want to miss.
Lastly, here are parting messages from Dafna and David for young scientists:
Dafna: It’s really important to follow your brain and your heart in terms of what it is you want to do. Don’t get sidetracked by the flashiness of a methodology or by the fact that a certain phenomenon has been published in a high-profile paper. Use your creativity and your curiosity to drive what you’re doing. From my experience, that has been the most important ingredient for success and what is ultimately most rewarding. So really think about the interesting questions, don’t shy away from the more difficult questions, rise up to the challenge and do whatever you can to meet it.
David: If someone’s really interested in pancreatic cancer, they should find people they can start working with and talking with now. They should contact the participants – the course instructors and students – to seek from them any knowledge about the course that could help them on their quest to learn more about pancreatic cancer. And pretty much anyone who’s a lecturer in this course is more than happy to help someone get started on their path.
Thank you to Dafna, Howard, Tony, and David for taking the time to chat with us. For more conversations with our other meeting organizers and course instructors, go here. Also, to gain a trainee's perspective on the Ion Channels course, read our Q&A with Lee Shaashua.